Umbilical Cord Blood As A Regulated Source Of Starting Material

Did you know that umbilical cord blood is an FDA-approved source of starting material for cell therapies? In this segment from the Cell & Gene Live digital event Stem-Cell Derived Therapies: From Source To Site, Colleen Delaney, MD, Founder, CSO, EVP of R&D at Deverra Therapeutics, and CSO and CMO at Coeptis Therapeutics, makes the case for using cord blood as a starting material for stem cells and stem-cell derived therapies. She also touches on the scalability of cord blood in pooled donor manufacturing.